RxDoctor Payments Data

Joseph Fishkin, MD

Ophthalmology · Emerson, NJNPI 1407953540

Payments from drug & device makers

$1,659in general payments, 2019–2025

Across 69 payments — averaging $24.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$432
  • Glaukos Corporation$205
  • Bausch & Lomb Americas Inc.$146
  • AbbVie$129
  • Sun Pharmaceutical Industries Inc.$124
  • Biotissue Holdings Inc.$123
  • plus $500 from 10 others

What the payments were for

  • Food & beverage$1,64199%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,659 in reported general payments places this provider in the 50th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$257,489
Medicare patients
895
Services billed
2,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine79$84,326
XiidraLifitegrast26$42,408
Cyclosporine37$19,337
LumiganBimatoprost17$12,635
TyrvayaVarenicline Tartrate12$8,537
Prednisolone Acetate105$6,209
Travoprost23$4,410
CombiganBrimonidine Tartrate/Timolol15$3,939
Timolol Maleate44$3,353
Latanoprost161$2,111
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,993
Ofloxacin100$1,554
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha119$1,316
Brimonidine Tartrate11$552
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$129$100,900111 claims
Bausch & Lomb Americas Inc.Xiidra$146$42,40826 claims
Oyster Point Pharma, Inc.Tyrvaya$119$8,53712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Emerson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →